Evaluation and clinical validation of pan-specific and clade-specific diagnostic real-time PCR assays for human mpox virus

Hong Chang, PhD[1,2,^], Tin Hang Hung, DPhil[3,^] (iD), Binbin Li, MVM[1], Bobby Lim Ho Kong, PhD[2] (iD), Yue Wang, BSc[1], Ming-shan Tsai, DPhil[2] (iD), Dan Deng, MD, PhD[4] (iD), Zhanfeng Cui, PhD, DSc[1,5,*]

1. Oxford Suzhou Centre for Advanced Research (OSCAR), University of Oxford, Suzhou Industrial Park, Jiangsu, 215123, China
2. ZYTCA Limited, Centre for Innovation and Enterprise, Begbroke Science Park, Oxford, OX5 1PF, United Kingdom
3. Department of Biology, University of Oxford, OX1 3RB, United Kingdom
4. Department of Dermatology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
5. Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, OX3 7DQ, United Kingdom

^H.C. and T.H.H. contributed equally as co-first authors.

Corresponding author:
*Z.C.: zhanfeng.cui@eng.ox.ac.uk

Summary

Background

Human mpox, formerly known as human monkeypox, has been twice declared a

Public Health Emergency of International Concern (PHEIC) in May 2022 and August 2024

by the World Health Organization (WHO). Equitable access to mpox testing is still

questionable because of limited testing capacity, hampering efforts in controlling the

outbreak. Our objective is to develop a rapid direct real-time PCR assay to detect and

differentiate Clade I and Clade II MPXV in clinical samples.

Methods

We designed a new pan-specific B15L assay to be used with previously published

F3L assay and the first clade-specific B1R assay, using publicly available MPXV genomes.

We conducted *in silico* inclusivity test to validate that B15L and F3L assay could detect all

available MPXV genomes and *in silico* specificity test to validate that B1R assay would only

detect Clade I genomes. Thus, when combined together, the two assays could detect and

differentiate MPXV. We also conducted *in silico* cross-reactivity test to rule out potential off-

target detection in closely related (e.g. Family Poxviridae) and common organisms (e.g.

human). We then used *in vitro* methods to validate the sensitivity and specificity of the assays.

Finally. we incorporated our assays into a direct PCR system and clinically validated the

lyophilised, ready-to-use format for detecting MPXV. We used human lesion samples to

create a clinical negative matrix spiked with MPXV standards and validated the sensitivity of

our assays in clinical samples.

Findings

Both pan-specific B15L and F3L assays could detect all publicly available MPXV

genomes *in silico*, thus a 100% sensitivity. Clade-specific B1R assays could detect all Clade I

genomes but none of the Clade II genomes *in silico*, thus a 100% sensitivity and specificity.

The assays were highly specific for MPXV out of 40 non-target high-priority organisms

tested, with an exception that 2 out of 5 cowpox virus genomes could potentially be detected

but they were very unlikely to be found in human clinical samples. *In vitro* analyses

confirmed an analytical sensitivity of 2 copies per reaction for all assays and 100% specificity

for clade-specific B1R assay. In the clinical validation experiment, we further confirmed an

analytical sensitivity of 1 copy per reaction for pan-specific B15L+F3L assay and 2 copies

per reaction for clade-specific B1R assay.

Interpretation

Our assay for the diagnosis of mpox displayed superior performance as a direct real-
time PCR method for near-point-of-care testing, which delivers results in under 1 hour. Our
assay demonstrated perfect sensitivity and specificity in *in silico*, *in vitro*, and clinical
validation experiments. The analytical sensitivity of 2 copies per reaction was incomparable
with existing solutions. We believe this study presents exceptional promise in response to the
ramping up of emergency use diagnostics by WHO.

Keywords: mpox, pandemic, diagnostics

Research in context

Evidence before this study

We did a search of primary research articles published in PubMed up until 1 February

2025, using the search terms "monkeypox", "mpox", and "MPXV" combined with "real-time

PCR", and "diagnostics". Six studies could be identified. However, these studies were limited

in terms of ability to differentiate between MPXV clades, lack of clinical validation, or lack

of cross-reactivity validation.

Added value of this study

We developed and evaluated an assay for MPXV detection using direct real-time PCR

which had a sample-to-result turnaround of 1 hour. Using *in silico* analyses, we confirmed

that our clade-specific assay had 100% sensitivity and specificity, and the pan-specific assay

had 100% sensitivity with only unlikely cross-reactivity with cowpox virus. Importantly,

clinical validation demonstrated very high analytical sensitivity (2 copies per reaction).

Implications of all the available evidence

In line with WHO instructions and requirements for emergency use listing submission

on *in vitro* diagnostic testing of MPXV, we believe this study presents exceptional promise in

response to the ramping up of disease surveillance and control.

Introduction

Human mpox, formerly known as monkeypox, has emerged as a significant public

health concern, particularly highlighted by the World Health Organization's (WHO) two-time

declaration of a Public Health Emergency of International Concern (PHEIC) in May 2022

and August 2024. Infected individuals may experience fever, lymphadenopathy, and a

characteristic rash that might lead to secondary infection. Immunocompromised individuals

are more vulnerable to severe manifestations of the disease, and in the most severe cases,

death. This zoonotic viral disease, caused by the monkeypox virus (*Orthopoxvirus*

monkeypox, also known as MPV, MPXV, and hMPXV) first isolated in laboratory monkeys

in Denmark in 1958[1], has recently seen a dramatic increase in global cases, with over 100,000

infections   and   230   deaths   (accessed   10   November   2024   from

https://worldhealthorg.shinyapps.io/mpx_global/[2]).

MPXV has a complex phylogenetic history, primarily categorized into two main

clades: Clade I and Clade II. Clade I, also known as the Central African clade, is associated

with higher mortality rates, while Clade II, which includes the West African clade, has been

linked to milder disease outcomes[3–5]. Historically both only led to endemic outbreaks, but the

recent global outbreak of mpox since 2022 was caused by an emerging lineage B.1 in the

sub-Clade IIb in Europe around May 2022[6,7], the first PHEIC. This lineage has shown

significant genetic divergence and rapid mutation rates, raising concerns regarding its

transmissibility and potential for further adaptation[8,9]. Additionally, the emergence of Clade

Ib, which causes a more widespread endemic outbreak in the Democratic Republic of Congo,

has shown increased human-to-human transmission[10] and thus the second PHEIC. In

November 2024, United Kingdom confirmed the first local transmission of Clade Ib mpox

outside Africa since the onset of second PHEIC[11].

The emergence of new strains is particularly alarming as they may exhibit enhanced

transmissibility and virulence, posing a substantial public health threat[12]. WHO has already

added MPXV to the list of priority pathogens that might cause a pandemic. The global spread

of Clade IIb, coupled with the escape of Clade I from endemic areas, underscores the

necessity for vigilant surveillance to mitigate and contain the risk of a pandemic.

Molecular diagnostics plays a crucial role in mitigating the risk of pandemic by

enabling mass screening and rapid identification, as we learned from the immediate past

lesson from the COVID-19 pandemic[13]. The early evidence such as Switzerland proved that

rapid turnaround of molecular diagnostics with rapid contact tracing was effective in disease

control[14]. Among various diagnostic methods available, real-time polymerase chain reaction

(RT-PCR) assays remain the gold standard for its high sensitivity and specificity, especially

useful for low target level when pathogen loads may still be minimal in early stages of

infection[15]. The quantitative nature also offers significance in monitoring viral load and

estimating infectivity[16]. However, traditional real-time PCR systems require expensive

equipment and highly trained professionals to operate, significantly limiting their use to well-

equipped laboratories.

The Target Product Profiles (TPP) for published by WHO[17] in 2023 has highlighted

the pressing need for more affordable, simplified, and decentralized diagnostic kits for mpox

in outbreak regions. While several commercial mpox real-time PCR kits have been available

since the PHEIC declaration in 2022, all currently require DNA extraction and purification

steps to eliminate PCR inhibitors commonly found in clinical samples, only suitable for

clinical laboratories when handling large volume of tests[18]. Moreover, none of the kits

approved under the WHO Emergency Use Listing (EUL) or CDC Emergency Use

Authorization (EUA) can differentiate between MPXV Clades I and II, despite this being one

of the preferred characteristics outlined in the WHO mpox TPPs.

The overarching goal of this paper is to develop clade-specific diagnostic primers and

probes for integration into real-time PCR assay. First, we describe how we optimise the

primer design algorithm based on the openly available genomic data. Second, we evaluate

their sensitivity and specificity in differentiating the MPXV clades in both *in silico* and *in*

vitro tests. Third, we validate the performance of our assay on human clinical samples that

were spiked with synthetic MPXV DNA fragments and evaluate its analytical sensitivity.

139 Methods

MPXV pan-specific primer design and screening

We downloaded all complete genomic data of MPXV (NCBI Taxon: 10244) using
NCBI Datasets. We also followed the WHO instructions and requirements for emergency use
listing submission on *in vitro* diagnostic testing of MPXV nucleic acid (PQDx_457 version;
10 September 2024) in obtaining a list of 40 non-target high priority organisms
(**Supplementary Table 1**), including same-family viruses such as smallpox virus, camelpox
virus, and buffalopox, and other common contaminants such as herpes simplex virus,
streptococcus, and human genomic DNA.

We mapped all MPXV genomic sequences to the reference genome NC_003310.1
and conducted multiple sequence alignment using ViralMSA 1.1.30. We then designed
mpox-specific primer using the real-time PCR mode in varVAMP 1.2.1 mode and screened
primers that might bind to non-target genomes using blastn 2.16.0. All candidates for primers
and probes were aligned to the reference and non-target genomes to inspect their sequence
similarity and predict their binding efficiency. We picked the highest-confidence primers and
probes targeting the **B15L** loci and obtained the primers and probes synthesised by Integrated
DNA Technologies (United Kingdom). We also included another previously designed primer
scheme on **F3L**[19]. Sequences and statistics for all primers and probes listed in this study
could be found in **Supplementary Table 2**.

MPXV clade-specific primer design

With reference to the previous phylogenetic study[20], 56 MPXV genomes were chosen
for the clade-specific primer design. Among the 56 genomes, 2 of them were reference
genomes for Clade I (NC_003310) and Clade II (NC_ 063383) MPXV, while the other 54
were public genomic resources in NCBI (**Supplementary Table 3** of their accession & origin
& clades in supp). We aligned the genomes by using MAFFT version 7 (https://mafft.cbrc.jp).
Clade-specific regions were screened based on an indel observed in the B1R loci based on the
multiple sequence alignment, where an ~2.5 Kb-insertion in Clade II would prevent real-time
PCR amplification. We manually designed clade-specific primers and probes that flanked the
B1R loci.

Homology analysis

We analysed the sequences of primers and probes of B15L, F3L, and B1R for

homology with full-length genomic sequences attained from Nextstrain. Nextstrain contained

473 Clade Ia sequences, 128 Clade Ib sequences, 25 Clade IIa sequences, and 221 Clade IIb

sequences. We ran blastn 2.16.0 with the following command due to the nature of primer and

probe sequences: `-task blastn-short -word_size 7 -evalue 100 -perc_identity 80 -reward 2 -

penalty -3 -gapopen 2 -gapextend 1 -dust no`, which increased sensitivity for short sequences,

retained alignments with weaker statistical significance, and permitted small indels with

minimal penalties. We also manually crosschecked the homology results and the sequences

and removed those that contained significant number of unknown bases, as stretches of 'N',

in our target amplicons. The final analyses contained 393 Clade Ia sequences, 55 Clade Ib

sequences, 25 Clade IIa sequences, and 217 Clade IIb sequences.

In silico inclusivity test for MPXV pan-specific primers

We used R version 4.4.0 to analyse the homology results and potential amplification

successes. First, all the homology hits from blastn were sorted based on the genomic

coordinates for each of the two primer sets (B15L and F3L). Then, potential amplification

success was determined if the hits from forward primer, probe, and reverse primer, or the

reverse way, were consecutive.

We then visualised two statistics. First, we calculated the sensitivity, which was

calculated as the number of potential amplification success divided by the total number of

genomes tested, for each of the four sub-clades. Second, for those with potential

amplification success, we calculated the sequence identity for each genomic sequence on the

four sub-clades.

In silico specificity test for MPXV clade-specific primers

We ran the same blastn command as above using B1R Clade I-specific primers and

probe with the same full set of MPXV genomic sequences and the same R analysis as above

to analyse potential amplification successes.

We determined potential amplification successes by both the consecutive homologies

of forward primer, probe, and reverse primer, and the potential amplicon length. While there

is no absolute consensus on the limit of amplicon length by real-time PCR, most guidelines

recommend < 200 bp for optimal efficiency. We used < 1,000 bp as the criterion for potential

success.

In silico cross-reactivity test with other non-target organisms

206   We analysed the sequences of primers and probes for homology with full-length

genomic sequences for 40 non-target high-priority organisms as above. We searched the meta

data of complete genomes for each of the organisms using their NCBI Taxonomy IDs with

NCBI Datasets command-line tools version 16.29.0. We then randomly selected 5

representative genomes for each organism and merged all the genomes into a single sequence

file. List of randomly selected representative genomes could be found in **Supplementary**

Table 4. We ran blastn 2.16.0 with the same parameters as above.

213   We then used R version 4.4.0 to analyse the homology results and potential

214   amplification successes as above.

215   We then visualised two statistics. First, we calculated the frequency of potential

216   homology, which was calculated as the number of homology hits from blastn divided by the

217   total number of genomes tested, for each of the four sub-clades. Second, we reported the

218   average sequence similarity.

220   *In vitro* MPXV direct real-time PCR assay

221   For MPXV quantification in subsequent *in vitro* analyses, real-time PCR assays were

performed with 20-µl reactions, which contained 10 µl 2× Lyo PCR Master Mix (Apto-Gen

Ltd, United Kingdom), 5 µl primer-probe pre-mix (200nM B15L and F3L pan-specific

primers and 100nM probe; or 400nM B1R Clade I-specific primer and 200nM probe), and 5

µl samples (viral samples or synthetic DNA standards), using a QuantStudio 5 Real-Time

PCR System (Thermo Fisher Scientific, USA). The thermocycling profile for RT-PCR was as

follows: an initial denaturation at 95°C for 1 min, followed by 40 cycles of 95°C for 10 s and

60°C for 15 s. Signal was collected after each cycle.

Synthesis of MPXV genomic standards and establishment of standard curve

We designed two synthetic standards (Integrated DNA Technologies, USA) for

MPXV genomes using the multiple sequence alignment obtained from above: an 877-bp

Clade I-like sequence that contained sequences of F3L, B15L and B1R genes; and a 618-bp

Clade II-like sequence that contained sequences of F3L, B15L and D13L genes. The

sequences of the MPXV synthetic standards can be found in **Supplementary Table 5**.

Synthetic MPXV genomic DNA standards were first diluted by 1X IDTE buffer

(Integrated DNA Technologies, United Kingdom) to 10 ng/µl. Accurate concentration of the

stock DNA standard was then determined by Qubit dsDNA Quantification Broad Range

Assay Kit (Thermo Fisher Scientific, USA). DNA copy number and dilution volume were

calculated with Thermo Scientific Web Tools. Then, DNA standards were serially diluted

(10-folds, from 10^6 to 10^0 copies/µl) and real-time PCR was performed on QuantStudio™ 5

Real-Time PCR System (Thermo Fisher Scientific, USA). Experiment was triplicated for

each concentration, and the mean and standard deviation of the C_t value was calculated. In

order to establish the standard curve, the mean of C_t was plotted against the $\log_{10}$ (DNA copy

number), with error bars showing the standard deviation. By using the model of linear

regression, the equation, hence the slope (m) and goodness of fit (R^2) of the standard curve

were obtained. The amplification efficiency (E) was calculated by using the following

formula: $E = [10^{(-1/m)} - 1] \times 100\%$.

In vitro sensitivity for MPXV primers

We first evaluated the analytical sensitivity of each primer set (pan-specific B15L and

F3L and Clade I-specific B1R) by determining the tentative limit of detection (LoD), which

was defined as the lowest amount of target compound in a sample that could be accurately

measured by the primer. Real-time PCR reaction was run for each set of primer pairs.

Experiment was triplicated with a range of synthetic DNA concentrations (2×10^4, 2×10^3, 2

$\times 10^2$, 2×10^1, 2×10^0 and 2×10^{-1} copies/reaction). Tentative LoD was estimated when

positive detection was below 100%. To confirm the experimental sensitivity of each primer,

experiment was repeated for 20 replicates, with sample concentration at the tentative LoD.

The analytical LoD was confirmed when MPXV was positively detected in 95% of the

replicates.

In vitro specificity of MPXV pan-specific and Clade I-specific primer

In order to determine the experimental specificity of MPXV pan-specific and Clade I-

specific primer, real-time PCR assays were performed with 2,000-copies MPXV Clade II

synthetic standard. Specificity of MPXV pan-specific and Clade I-specific primer (B1R) was

then estimated by the numbers of true positives and false negatives.

Acquisition and preparation of clinical matrix

We obtained 50 human skin lesion swab samples from the Department of

Dermatology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong

University. Details of the sample types could be found in **Supplementary Table 6**. This

study was approved by the Institutional Review Board of Shanghai Children's Medical

Center (SCMCIRB-K2025018-1). Anonymised clinical samples were provided to Oxford

Suzhou Centre for Advanced Research for processing.

To prepare the MPXV-negative clinical matrix, 500 µL of RNase-free water was

added to each of the 50 wab tubes, which were then vortexed for 10 minutes. Then, 200 µl of

supernatant from each tube was pooled into a single 50-ml centrifuge tube, and the total

volume was adjusted to 10 ml. Finally, the matrix was aliquoted and stored at –80°C.

Clinical validation of analytical sensitivity

We incorporated our assay into the UlfaQ™ Direct PCR system (ZYTCA Ltd, United

Kingdom) (**Figure 1**), which contained an enhanced reaction buffer that eliminated effects of

inhibitors. We added 16 µl of MPXV-negative clinical matrix and 25 µl UlfaQ Sample

Processing Control (SPC) into 500 µl of UlfaQ lysis buffer, then spiked in 4 µl of our MPXV

synthetic standard. We included standards of six different concentrations (150, 125, 100, 75,

50, and 0 copy/ml) and a negative control (without SPC). We tested Clade I and Clade II

separately thus in total we had 14 matrices.

For each matrix, we transferred 20 µl of the lysate into a pre-lyophilised reaction

master mix (Tube A) which contained UlfaQ™ Direct PCR mix and our MPXV primers and

probes. Another 20 µl of the lysate was also added in the lyophilised internal control assay

(Tube B) targeting SPC and human beta-actin gene. We performed RT-PCR on three

replicates for each matrix on QuantStudio™ 5 Real-Time PCR System (Thermo Fisher

Scientific, USA). The thermocycling profile for real-time PCR was as follows: an initial

denaturation at 95°C for 1 min, followed by 40 cycles of 95°C for 5 seconds and 60°C for 10

seconds.

The analytical sensitivity of our assay was determined in similar approach as

described above. Tentative LoD was estimated when positive detection was below 100%. To

confirm the analytical sensitivity of each primer, experiment was repeated for 20 replicates,

with sample concentration at the tentative LoD. The analytical sensitivity was confirmed

when MPXV was positively detected in 95% of the replicates.

Results

In silico inclusivity test for MPXV pan-specific primers (B15L and F3L)

We found that both B15L and F3L primers were highly successful in amplifying MPXV across the four sub-clades (**Figure 2a**). Both assays achieved 100% *in silico*-predicted sensitivity for MPXV across all subclades, including 393 Clade Ia, 55 Clade Ib, 25 Clade IIa, and 217 Clade IIb genomes.

We found > 90% sequence similarity for all primers and probes (**Figure 2b and c**). Specifically, all B15L and F3L primers had 100% sequence similarity with the genomic targets, except 3 outliers for each. B15L probe had a consistent 96% sequence similarity with the genomic targets across all sub-clades. F3L probes had a consistent 100% sequence similarity with the genomic targets across all-subclades except the median sequence similarity for sub-Clade IIa was 96%.

In silico sensitivity and specificity test for MPXV clade-specific primers (B1R)

We found that B1R primers and probes were highly specific for MPXV Clade I (**Figure 2d**). The median predicted amplicon length for both sub-Clade Ia was 134 bp and Ib was 134 bp and that for sub-Clade IIa and IIb was 2,379 bp and 2,398 bp respectively. All 393 Clade Ia and 55 Clade Ib were predicted to amplify, while none of the 25 Clade IIa and 217 Clade IIb genomes were predicted to amplify. Thus, the sensitivity and specificity for B1R assay was 100%.

In silico cross-reactivity test with other non-target organisms

We analysed the sequences of primers and probes for homology with full-length genomic sequences for 40 non-target high-priority organisms as above. Homology was found between primers and Poxviridae viruses, more specifically, buffalopox, camelpox, cowpox, and mousepox viruses (**Figure 3a–c**), where some primers were found to have homology hits in blast in all genomes. However, for the vast majority of them the average sequence similarity was sufficiently low, except for B1R forward primer, which shared a 96% similarity with all buffalopox, cowpox virus, and mousepox viruses (**Figure 3d–f**).

We predicted that the only potential off-target amplification would be B15L on cowpox virus. Out of the five genomes tested, two genomes (HQ407377.1 and KY369926.1)

showed >80 % sequence similarity with all forward primer, probe, and reverse primer of

B15L (**Supplementary Table 7**).

Standard curve and assay performance

MPXV Clade I synthetic DNA was used to create standard curve and evaluate the

performance of the real-time PCR assay. The detection of the real-time PCR reactions was

linear over six 10-fold dilutions (2×10^6 to 2×10^1 copies/reaction) with a correlation

coefficient 1.0, for both MPXV pan-specific primers and Clade I-specific primer (**Figure 4a**

and **Supplementary Table 8**). Due to the high variance of Ct value at low copy number, the

data of Ct value at 2 copies/reaction was omitted in plotting the standard curve. Amplification

efficiency was high for both primer sets, in which all of them were 90–110%. No false

positive was observed in the triplicated reactions, indicating the reliability of the proposed

real-time PCR assays.

In vitro analytical sensitivity for B15L, F3L, and B1R

To determine the tentative LoD of each primer set in standard laboratory settings,

real-time PCR assays were triplicated with MPXV synthetic standard over six concentrations

(2×10^4, 2×10^3, 2×10^2, 2×10^1, 2×10^0 and 2×10^{-1} copies/reaction). All primer sets could

successfully amplify the target at an input amount of 2 copies, the tentative LoD (**Figure 4b**

and **Supplementary Table 9**). To confirm the experimental sensitivity of each primer set, all

primer sets demonstrated 100% sensitivity when repeated for 20 reactions at an input amount

of 2 copies (equivalent to 100 copies/ml), confirming the analytical LoD in standard

laboratory condition (**Figure 4c** and **Supplementary Table 10**).

In vitro specificity of MPXV Clade I-specific assay B1R

To evaluate the specificity of MPXV Clade I-specific primer, real-time PCR was

performed by using MPXV Clade II synthetic standard. Pan-specific assay (B15L+F3L)

successfully detected 2,000 copies of MPXV Clade II synthetic standard, while Clade I-

specific primer (B1R) showed no amplification (**Figure 4d**). The triplicated experiment

confirmed the specificity of MPXV Clade-I specific primer to be 100%.

Clinical validation of analytical sensitivity

For MPXV Clade I synthetic standard, we successfully detected positive signals in all

triplicates at 3, 2.5, 2, 1.5, and 1 copies/reaction for B15L+F3L pan-specific assay and at 3,

2.5, and 2 copies/reaction for B1R Clade I-specific assay (**Figure 5a** and **Supplementary**

Table 11). We thus estimated the tentative LoD for Clade I to be 2 copies/reaction

(equivalent to 100 copies/ml). We further validated the LoD with 20 replicates. All replicates

gave positive signals and thus confirmed the analytical sensitivity with high confidence

(**Figure 5b** and **Supplementary Table 12**).

For MPXV Clade II synthetic standard, we successfully detected positive signals in

all triplicates at 3, 2.5, 2, 1.5, and 1 copies/reaction for B15L+F3L pan-specific assay (**Figure**

5c and **Supplementary Table 13**). We thus estimated the tentative LoD for Clade II to be 1

copy/reaction (equivalent to 50 copies/ml). We further validated the LoD with 20 replicates.

All replicates gave positive signals and thus confirmed the analytical LoD with high

confidence (**Figure 5d** and **Supplementary Table 14)**. In addition, none of the replicates at

any concentration of Clade II standard gave positive signals for B1R Clade I-specific assay,

thus confirming the perfect specificity to differentiate MPXV clades.

Discussion

This study presents an integrated pan-specific and clade-specific near-point-of-care

diagnostic assay for human mpox diagnostics, which has been *in silico* validated with

existing genomic database and *in vitro* validated with synthetic standards and tested for limit

of detection.

Our assay included two new target regions, pan-specific B15L and clade-specific B1R,

and a verified pan-specific F3L. The function of B15L (IL-1 beta inhibitor) gene is not yet

reported but other IL-1 beta inhibitors might interfere with host cell signalling pathways,

further aiding the virus in evading immune detection and response[21]. The B1R gene encodes

for a BTB-Kelch-domain protein and has a frameshift mutation and a within-gene deletion in

Clade I MPXV[22], and thus initiates translation at a different start codon between Clade I and

IIb MPXV, resulting in different fragments of the protein. It is also suggested a close

homologue of B1R gene might inhibit the NFκB pathway and stimulates CD8+ T cell

proliferation but a similar function in MPXV is yet to confirmed[23]. The F3L encodes an

enzyme with a double-stranded RNA binding domain and might be responsible for a broad

spectrum of antiviral immune responses[24] and circumventing apoptosis to achieve productive

replication[23] in the host.

Through *in silico* approaches, we have validated hat the MPXV pan-specific assays

targeting B15L and F3L showed perfect sensitivity to historical and contemporary MPXV

genomes across different lineages of sub-clades. Most importantly, our clade-specific B1R

assay is proven to also have absolute sensitivity and specificity to Clade I MPXV. Therefore,

when combined with use of either B15L and F3L as the pan-specific assay, one could

efficiently discriminate the two clades: Clade I for both B1R and B15L/F3L were positive

and clade II for B1R negative but B15L/F3L positive. The diagnostic assay was made most

efficient in a duplex real-time PCR, where each probe can be labelled with a different

fluorophore (i.e. FAM and HEX). Our direct real-time PCR, clade-specific assay would be

directly addressing a significant gap in disease surveillance, as there is still no WHO-

approved antigen-based RDT or point-of-care tests that can distinguish between mpox

clades[25] and the rapid turnaround time would reduce time and financial cost for genotyping in

central laboratories.

We also thoroughly ruled out potential cross reactivity with other closely related

viruses and common contaminants in clinical samples. All B15L, F3L, and B1R showed a

very high degree of specificity even among evolutionary relatives, such as buffalopox,

camelpox, cowpox, and mousepox viruses. There are occasionally matches to B15L primer

and probe sequences with cowpox viruses. However, cowpox is very rare and only a few

hundred cases have ever been reported[26]. There is also no reported case of human-to-human

transmission[27]. Therefore, a false positive result due to cowpox infection would be highly

unlikely. We thus remain confident that our B15L, F3L, and B1R assays demonstrate

excellent sensitivity and specificity to MPXV.

The analytical sensitivity of our assay, 2 copies per reaction for MPXV Clade I and 1

copy per reaction for MPXV Clade II, demonstrated utility in detecting extremely low

amount of MPXV genomes. Our sensitivity is more superior than any assay reported on

mpox, including Li et al.'s at 3.5–40.4 copies[28], Maksyutov et al.'s at 20 copies[19], Li et al.'s

at 15 copies[29], Mills et al.'s at 3.3 copies[30], and Paniz-Mondolfi et al.'s at 7.2 copies[31], except

Uhteg and Mostafa's also at 2 copies but theirs could not differentiate clades[32]. A lower LoD

allows for the detection of the virus even at early stages of infection when viral loads may be

minimal, crucial for identifying cases before significant viral replication occurs[30].

We believe that the robust sensitivity and specificity of our direct, multiplex, clade-

specific real-time PCR assay, that delivers results in under 1 hour, would be pivotal in early

detection, disease surveillance, and epidemic control of mpox, including prompt isolation of

infected individuals and epidemiological studies for implementing public health measures.

Figures

432
433   **Figure 1.** Graphical abstract of direct real-time PCR in clinical validation.

Figure 2. **(a)** *In silico*-predicted sensitivity for B15L and F3L across four MPXV sub-clades, calculated as number of potential amplification successes divided by total number of genomic sequences tested; and sequence identity for forward primer (FP), probe, and reverse primer (RP) for **(b)** B15L and **(c)** F3L across four MPXV sub-clades and two genomic databases (GISAID and Nextstrain). **(d)** Potential amplicon length using B1R primers across four MPXV sub-clades.

Figure 3. Frequency of homology hits between (**a**) forward primer, (**b**) probe, and (**c**) reverse primer for B15L, B1R, and
F3L and the genomic sequences of each non-target organism ($N = 5$, except for organisms that did not have five
representative genomes available). List of non-target organisms was determined from the relevant WHO guideline on mpox
testing. Average sequence similarity between (**d**) forward primer, (**e**) probe, and (**f**) reverse primer for B15L, B1R, and
F3L and the genomic sequences of each non-target organism ($N = 5$, except for organisms that did not have five representative
genomes available). List of non-target organisms was determined from the relevant WHO guideline on mpox testing.

450
451 **Figure 4. (a)** Standard curve of real-time PCR Ct value against copy numbers of MPXV synthetic standard for pan-specific
452 B15L+F3L primers and clade-specific B1R primers. Experiment was triplicated. **(b)** Tentative limit of detection (LoD)
453 determined by real-time PCR Ct value against copy number of MPXV synthetic standard. Experiment was triplicated. **(c)**
454 Analytical sensitivity confirmed by real-time PCR of 20 replicates at the tentative LoD. **(d)** Analytical specificity of Clade 1-
455 specific B1R on MPXV Clade II synthetic standard. NC denotes negative control.

456
457

458
Figure 5. (a) Tentative limit of detection (LoD) for MPXV Clade I synthetic standard determined by real-time PCR Ct value
against copy number of standard. Experiment was triplicated. **(b)** Analytical sensitivity for MPXV Clade I synthetic standard
confirmed by real-time PCR of 20 replicates at the tentative LoD. **(c)** Tentative limit of detection (LoD) for MPXV Clade II
synthetic standard determined by real-time PCR Ct value against copy number of standard. Experiment was triplicated. **(d)**
Analytical sensitivity for MPXV Clade II synthetic standard confirmed by real-time PCR of 20 replicates at the tentative
LoD.

References

1. Parker, S. & Buller, R. M. A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012. *Future Virol* **8**, 129 (2013).

2. World Health Organization. 2022-24 Mpox Outbreak: Global Trends. https://worldhealthorg.shinyapps.io/mpx_global/ (2024).

3. Gao, L. *et al.* Mpox, Caused by the MPXV of the Clade IIb Lineage, Goes Global. *Trop Med Infect Dis* **8**, 76 (2023).

4. Schwartz, D. A. & Pittman, P. R. Mpox (Monkeypox) in Pregnancy: Viral Clade Differences and Their Associations with Varying Obstetrical and Fetal Outcomes. *Viruses* **15**, (2023).

5. Saied, A. R. A. Mpox virus Clade IIb detection in the air. *J Med Virol* **95**, (2023).

6. Isidro, J. *et al.* Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. *Nature Medicine 2022 28:8* **28**, 1569–1572 (2022).

7. Cho, W. *et al.* Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: A systematic review and meta-analysis. *Rev Med Virol* **34**, (2024).

8. Dumonteil, E., Herrera, C. & Sabino-Santos, G. Monkeypox Virus Evolution before 2022 Outbreak - Volume 29, Number 2—February 2023 - Emerging Infectious Diseases journal - CDC. *Emerg Infect Dis* **29**, 451–453 (2023).

9. Dumonteil, E., Herrera, C. & Sabino-Santos, G. Monkeypox Virus Evolution before 2022 Outbreak. *Emerg Infect Dis* **29**, 451–453 (2023).

10. Vakaniaki, E. H. *et al.* Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. *Nature Medicine 2024 30:10* **30**, 2791–2795 (2024).

11. World Health Organization. First local transmissions of clade Ib mpox in the WHO European Region confirmed in the United Kingdom. https://www.who.int/europe/news/item/05-11-2024-first-local-transmissions-of-clade-ib-mpox-in-the-who-european-region-confirmed-in-the-united-kingdom (2024).

12. Obermeier, P. E. *et al.* Reemergence of Clade IIb–Associated Mpox, Germany, July–December 2023. *Emerg Infect Dis* **30**, 1416–1419 (2024).

13. Pritzker, K. Impact of the COVID-19 pandemic on Molecular Diagnostics. *Expert Rev Mol Diagn* **21**, 519–521 (2021).

14. Marcel, S. *et al.* Early evidence of effectiveness of digital contact tracing for SARS-CoV-2 in Switzerland. *Swiss Med Wkly* **150**, (2020).

15. Puhach, O., Meyer, B. & Eckerle, I. SARS-CoV-2 viral load and shedding kinetics. *Nature Reviews Microbiology 2022 21:3* **21**, 147–161 (2022).

16. Engstrom-Melnyk, J., Rodriguez, P. L., Peraud, O. & Hein, R. C. Clinical Applications of Quantitative Real-Time PCR in Virology. *Methods in Microbiology* **42**, 161 (2015).

17. World Health Organization. *Target Product Profiles for Tests Used for Mpox (monkeypox) Diagnosis.* (Geneva, 2023).

18. Samarasekera, U. WHO ramps up emergency use mpox diagnostics. *Lancet Microbe* **6**, 101051 (2025).

19. Maksyutov, R. A., Gavrilova, E. V. & Shchelkunov, S. N. Species-specific differentiation of variola, monkeypox, and varicella-zoster viruses by multiplex real-time PCR assay. *J Virol Methods* **236**, 215–220 (2016).

20. Djuicy, D. D. *et al.* Concurrent Clade I and Clade II Monkeypox Virus Circulation, Cameroon, 1979–2022. *Emerg Infect Dis* **30**, 432 (2024).

514   21.   Reynolds, M. G., Carroll, D. S. & Karem, K. L. Factors affecting the likelihood of
515   monkeypox's emergence and spread in the post-smallpox era. *Curr Opin Virol* **2**, 335–
516   343 (2012).
517   22.   Desingu, P. A., Rubeni, T. P., Nagarajan, K. & Sundaresan, N. R. Molecular evolution
518   of 2022 multi-country outbreak-causing monkeypox virus Clade IIb. *iScience* **27**,
519   108601 (2024).
520   23.   Alakunle, E. *et al.* A comprehensive review of monkeypox virus and mpox
521   characteristics. *Front Cell Infect Microbiol* **14**, 1360586 (2024).
522   24.   Wang, Y. *et al.* Transcriptome and proteomic analysis of mpox virus F3L-expressing
523   cells. *Front Cell Infect Microbiol* **14**, 1354410 (2024).
524   25.   Nemer, M. The world has responded too slowly to the new mpox outbreak – here's
525   what   it   needs   to   do   now.   *The   Guardian*
526   https://www.theguardian.com/commentisfree/2024/nov/21/world-responded-slowly-
527   mpox-outbreak (2024).
528   26.   Świtaj, K., Kajfasz, P., Kurth, A. & Nitsche, A. Cowpox after a cat scratch-case report
529   from Poland. *Annals of Agricultural and Environmental Medicine* **22**, 456–458 (2015).
530   27.   Wolfs, T. F. W., Wagenaar, J. A., Niesters, H. G. M. & Osterhaus, A. D. M. E. Rat-to-
531   Human Transmission of Cowpox Infection. *Emerg Infect Dis* **8**, 1495 (2002).
532   28.   Li, Y., Zhao, H., Wilkins, K., Hughes, C. & Damon, I. K. Real-time PCR assays for
533   the specific detection of monkeypox virus West African and Congo Basin strain DNA.
534   *J Virol Methods* **169**, 223–227 (2010).
535   29.   Li, Y., Olson, V. A., Laue, T., Laker, M. T. & Damon, I. K. Detection of monkeypox
536   virus with real-time PCR assays. *Journal of Clinical Virology* **36**, 194–203 (2006).
537   30.   Mills, M. G. *et al.* Evaluation and clinical validation of monkeypox (mpox) virus real-
538   time PCR assays. *Journal of Clinical Virology* **159**, 105373 (2023).
539   31.   Paniz-Mondolfi, A. *et al.* Evaluation and validation of an RT-PCR assay for specific
540   detection of monkeypox virus (MPXV). *J Med Virol* **95**, e28247 (2023).
541   32.   Uhteg, K. & Mostafa, H. H. Validation and implementation of an orthopoxvirus
542   qualitative real-time PCR for the diagnosis of monkeypox in the clinical laboratory.
543   *Journal of Clinical Virology* **158**, 105327 (2023).
544
545

Competing interests statement

T.H.H. is a scientific advisor and H.C., B.L.H.K., and M.-S.T. are employees of ZYTCA

Limited. Their conflicts of interest have been declared in the ICJME forms.

Data availability statement

All sequences and data pertaining to this study can either be found in Supplementary

Information or public databases. Accession numbers have been included in Supplementary

Information.

Author contributions

H.C.: conceptualisation, investigation, validation, project administration, supervision,

writing – review & editing;

T.H.H.: conceptualisation, formal analysis, investigation, methodology, validation,

visualisation, writing – original draft;

B.L.: data curation, formal analysis, investigation, writing – review & editing;

B.L.H.K.: conceptualisation, data curation, formal analysis, investigation, methodology,

writing – review & editing

Y.W.: data curation, investigation, writing – review & editing;

M.-S.T.: investigation, project administration, supervision, validation, writing – review &

editing

D.D.: data curation, funding acquisition, investigation, resources, writing – review & editing

Z.C.: conceptualisation, project administration, supervision, writing – review & editing

Acknowledgements

D.D. is supported by the National Natural Science Foundation of China (ref. 82173396).